Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and

Cristina R Antonescu1, Adepitan A Owosho, Lei Zhang

  • 1Departments of *Pathology †Surgery ¶Medicine, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Pathology, Erciyes University, Kayseri, Turkey §Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei ∥Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan #Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Insights

CIC-DUX4 gene fusions are common in EWSR1-negative small blue round cell tumors. These sarcomas, distinct from Ewing sarcoma, show aggressive behavior and poorer survival rates in young adults.

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • CIC-DUX4 gene fusions are the most common abnormality in EWSR1-negative small blue round cell tumors.
  • Previous classifications debated whether these are Ewing sarcoma variants or distinct entities.
  • Limited data existed on their clinical presentation, morphology, and outcomes.

Purpose of the Study:

  • To investigate the clinicopathologic features of a large cohort of CIC-rearranged sarcomas.
  • To define their clinical presentation, morphologic spectrum, and patient outcomes.
  • To compare the survival of CIC-rearranged sarcomas with EWSR1-rearranged Ewing sarcoma.

Main Methods:

  • Analysis of 115 patients with CIC gene rearrangement.
  • Morphologic evaluation, including cytomorphology and immunohistochemistry (CD99, WT1).
  • Genetic analysis for CIC-DUX4 fusion and comparison with a matched Ewing sarcoma cohort.

Main Results:

  • Most tumors occurred in soft tissues of young adults (mean age 32 years).
  • Morphology varied, including round, epithelioid, and spindle cells with myxoid changes.
  • CIC-DUX4 fusion detected in 57% of cases.
  • 5-year survival was 43% for CIC-rearranged sarcomas versus 77% for Ewing sarcoma (P=0.002).

Conclusions:

  • CIC-DUX4 sarcomas present a distinct clinicopathologic and molecular entity.
  • These tumors exhibit aggressive behavior and inferior survival compared to Ewing sarcoma.
  • The findings support classifying CIC-rearranged tumors as a separate subset of small blue round cell tumors.